Serum sickness following treatment with rituximab.
J Rheumatol
; 34(2): 430-3, 2007 Feb.
Article
in En
| MEDLINE
| ID: mdl-17295433
ABSTRACT
Serum sickness, an illness characterized by fever, rash, and arthralgias, can occur in patients who receive chimeric monoclonal antibody therapy. Rituximab, a B cell-depleting chimeric anti-CD20 monoclonal antibody, has been used with increasing frequency in the treatment of rheumatologic illnesses such as rheumatoid arthritis and systemic lupus erythematosus. Serum sickness has only rarely been reported following rituximab therapy. All prior reported cases have been in patients with autoimmune conditions. We describe a case of serum sickness in a patient treated with rituximab for mantle cell lymphoma. We also review the literature of rituximab-induced serum sickness.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Serum Sickness
/
Lymphoma, Mantle-Cell
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
J Rheumatol
Year:
2007
Document type:
Article
Affiliation country: